The foramen ovale is a door-like opening of the interatrial septum framed by the septum primum and septum secundum. In utero it serves as a pathway for oxygenated blood to shunt from the right to the left atrium, thereby bypassing the nonfunctional lungs. 
ulation no permanent closure occurs, and the patent foramen ovale (PFO) may allow particulate or chemical material to pass from the venous to the arterial circulation, especially during increased right atrial pressure (e.g., Valsalva manoeuvre). A PFO has been associated with cryptogenic stroke, myocardial infarction, migraines, sleep apnoea, platypnoea-orthodeoxia, diving-associated decompression illness and high-altitude pulmonary oedema. Nevertheless, the majority of humans with a PFO live without experiencing a PFO-related medical condition [1] . Therefore, the PFO does not qualify as a screening target in the general population [2] and primary prophylactic PFO closure in asymptomatic individuals is not recommended.
Stroke is one of the most feared and devastating health disorders. One third of strokes are so-called cryptogenic because no apparent cause is found. The prevalence of a PFO in patients suffering a cryptogenic stroke is higher than in patients with known stroke causes [3, 4] . Nonetheless, in a large number of patients with cryptogenic stroke, no PFO is found [4] . Given the 
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